The internal crisis gripping the has deepened as former and launched a robust defense against allegations leveled by the organization’s Vice-Chairmen, Venu Srinivasan and Vijay Singh. The confrontation, which has become increasingly public, centers on the proposed public listing of and the evolving governance model within the charitable trusts that control the holding company. Khambata’s four-page communication, dated , serves as a direct rebuttal to claims made by the Vice-Chairmen regarding his conduct, his strategy for appointments, and his stance on the tenure of Chairman N. Chandrasekaran.
The dispute arrives at a precarious time for the Tata Group. On , the (RBI) reiterated that must comply with regulations governing upper-layer , which includes the requirement to list its shares. This regulatory pressure, combined with internal disagreements regarding the group's leadership structure, has set the stage for a critical board meeting scheduled for , where the listing issue and potential restructuring are expected to dominate the agenda.
Challenging the Strategic Volte-Face
Central to Khambata’s grievance is the unexplained shift in position by Srinivasan and Singh regarding the public listing of . According to Khambata, the two Vice-Chairmen had consistently supported the anti-listing stance maintained by during meetings held in , , and . However, he notes that they pivoted in without providing a transparent rationale to their fellow trustees.
“My grievance is why you repeatedly voted to oppose listing but suddenly did a volte face in ,” Khambata wrote in his response. He emphasized that such critical strategic decisions should be the subject of rigorous debate within formal meetings of the Trusts, rather than being conducted through external correspondence or media statements.
The Vice-Chairmen have previously argued that listing would not dilute the charitable mission of the Trusts, drawing comparisons to global entities like Novo Nordisk, which operate under the umbrella of charitable foundations. Khambata, however, dismissed this comparison as fundamentally flawed, asserting that the existing governance structure of Novo Nordisk serves as a cautionary tale rather than a model for emulation. He maintains that the of the trustees is to protect the principal asset of the Trusts—the shareholding in —and that control is the "essence" of the Tata model.
Untangling the Leadership Controversy
The exchange also revisits the tumultuous process surrounding the reappointment of N. Chandrasekaran as the chairman of . Khambata rejects claims that his position on the leadership has been inconsistent. He maintains that he voted for Chandrasekaran’s third term in based on the strength of performance figures presented at that time, which he described as “very impressive.”
The conflict, according to Khambata, is not about the chairman’s performance but rather the procedural irregularities observed during the , board meeting. He pointed to a previous from , where all trustees had agreed to respect Chandrasekaran’s stated wish at the time not to seek reappointment and to initiate a selection process for a successor. Khambata has questioned whether Srinivasan, acting as a , brought this to the attention of the ’ Nomination and Remuneration Committee during its deliberations in September.
Furthermore, the former has strongly pushed back against allegations that he orchestrated a strategy to temporarily remove Srinivasan as a to shift the balance of power within the . He clarified that Srinivasan’s failure to secure reappointment in late 2025 was a result of conditions set by other trustees, such as Mehli Mistry, who expected adherence to a prior concerning the reappointment of all trustees. Khambata noted that he personally voted to reappoint Srinivasan on two separate occasions in 2025, a move he contends would have been irrational had he been acting as part of a clandestine strategy to oust him.
Governance and Fiduciary Responsibility
Khambata’s letter highlights a profound breakdown in communication within the leadership of the . He expressed profound disappointment that the accusations leveled against him were never addressed in the many meetings of the Trusts held over the past three years. “It is apparent that because I called out 17th September, I am now subjected to a personal attack,” he wrote, while clarifying that he remains committed to a of the dispute in the interests of the organization and its stakeholders.
The legal dimension of the dispute relies heavily on the interpretation of previous resolutions, including an , agreement that purportedly bound trustees to support each other’s reappointments. Khambata argues that this was disregarded by Srinivasan, Singh, and Chairman Noel Tata when they voted against the reappointment of Mehli Mistry. He further asserts that his commitment to the Tata model and his advocacy for the Trusts’ control over are rooted in his understanding of the judgment rendered by the .
As the board meeting approaches, the organization faces immense pressure to resolve these mounting personal and strategic divisions. With additional pressure from regulators and the recent public intervention by figures such as Jimmy N. Tata, the path forward remains uncertain. Khambata, while firm in his rebuttal, has expressed a desire to move past the personality-driven conflicts, suggesting that the leadership’s role should be to foster unity rather than further fracturing the institution. The focus now shifts to whether the board can reconcile the conflicting positions on listing and corporate control to satisfy regulatory directives while preserving the long-standing objectives of the Trusts.
corporate governance dispute - Tata Sons listing - trustee fiduciary duty - boardroom conflict - holding company structure